CVR number 26747007
Industry 20.5900 Manufacture of other chemical products n.e.c.

ELDON BIOLOGICALS A/S

 

Quicksearch
from your own companies
Analyst: XBRLDenmark
 
Loading...

Loading...

Loading...

Loading...

 
Loading...
Bankruptcy Risk 
2019
2020/6
2020
2021/6
2021
2022/6
2022
2023/6
2023
2024/6
Bankruptcy risk for industry  1.5% 1.5% 1.5% 1.5% 1.5%  
Bankruptcy risk  0.6% 0.6% 0.6% 0.7% 0.6%  
Credit score (0-100)  98 98 95 95 96  
Credit rating  AA AA AA AA AA  
Credit limit (kDKK)  2,800.0 4,242.4 4,673.2 4,758.7 5,453.3  
How are these values calculated?
 
View the automatically generated explanation of bankruptcy risk

Income statement (kDKK) 
2019
2020/6
2020
2021/6
2021
2022/6
2022
2023/6
2023
2024/6
Net sales  0 0 0 0 0  
Gross profit  14,331 19,531 16,383 12,307 14,865  
EBITDA  8,073 11,499 10,219 6,752 7,442  
EBIT  7,666 11,095 9,828 6,346 7,090  
Pre-tax profit (PTP)  8,476.4 11,569.4 6,187.6 6,853.2 8,502.6  
Net earnings  6,608.7 9,098.4 4,971.8 5,362.7 6,673.6  
Pre-tax profit without non-rec. items  8,476 11,569 6,188 6,853 8,503  
 
See the entire income statement

Balance sheet (kDKK) 
2019
2020/6
2020
2021/6
2021
2022/6
2022
2023/6
2023
2024/6
Tangible assets total  1,385 1,173 782 462 171  
Shareholders equity total  16,549 25,147 29,619 34,482 40,156  
Interest-bearing liabilities  2,678 3,313 914 561 748  
Balance sheet total (assets)  21,972 32,347 35,482 39,588 46,713  
Net Debt  -11,798 -23,413 -26,785 -26,480 -25,713  
 
See the entire balance sheet

Volume 
2019
2020/6
2020
2021/6
2021
2022/6
2022
2023/6
2023
2024/6
Net sales  0 0 0 0 0  
Net sales growth  0.0% 0.0% 0.0% 0.0% 0.0%  
Gross profit  14,331 19,531 16,383 12,307 14,865  
Gross profit growth  50.3% 36.3% -16.1% -24.9% 20.8%  
Employees  8 11 9 10 11  
Employee growth %  31.6% 36.1% -14.8% 6.7% 5.4%  
Employee expenses  0.0 0.0 0.0 0.0 0.0  
Balance sheet total (assets)  21,972 32,347 35,482 39,588 46,713  
Balance sheet change%  44.1% 47.2% 9.7% 11.6% 18.0%  
Added value  8,073.3 11,499.5 10,219.2 6,737.7 7,442.3  
Added value %  0.0% 0.0% 0.0% 0.0% 0.0%  
Investments  -259 -616 -782 2,062 1,854  
Net sales trend  0.0 0.0 0.0 0.0 0.0  
EBIT trend  4.0 5.0 5.0 5.0 5.0  

Profitability 
2019
2020/6
2020
2021/6
2021
2022/6
2022
2023/6
2023
2024/6
EBITDA %  0.0% 0.0% 0.0% 0.0% 0.0%  
EBIT %  0.0% 0.0% 0.0% 0.0% 0.0%  
EBIT to gross profit (%)  53.5% 56.8% 60.0% 51.6% 47.7%  
Net Earnings %  0.0% 0.0% 0.0% 0.0% 0.0%  
Profit before depreciation and extraordinary items %  0.0% 0.0% 0.0% 0.0% 0.0%  
Pre tax profit less extraordinaries %  0.0% 0.0% 0.0% 0.0% 0.0%  
ROA %  46.9% 44.6% 31.2% 19.5% 20.3%  
ROI %  53.0% 50.5% 35.6% 22.2% 22.8%  
ROE %  49.0% 43.6% 18.2% 16.7% 17.9%  

Solidity 
2019
2020/6
2020
2021/6
2021
2022/6
2022
2023/6
2023
2024/6
Equity ratio %  75.3% 77.7% 83.7% 87.1% 86.0%  
Relative indebtedness %  0.0% 0.0% 0.0% 0.0% 0.0%  
Relative net indebtedness %  0.0% 0.0% 0.0% 0.0% 0.0%  
Net int. bear. debt to EBITDA, %  -146.1% -203.6% -262.1% -392.2% -345.5%  
Gearing %  16.2% 13.2% 3.1% 1.6% 1.9%  
Net interest  0 0 0 0 0  
Financing costs %  9.1% 18.0% 207.1% 60.7% 39.8%  

Liquidity 
2019
2020/6
2020
2021/6
2021
2022/6
2022
2023/6
2023
2024/6
Quick Ratio  3.5 4.1 5.7 6.7 6.9  
Current Ratio  3.9 4.4 6.0 7.3 7.4  
Cash and cash equivalent  14,475.4 26,726.5 27,698.5 27,040.7 26,460.8  

Capital use efficiency 
2019
2020/6
2020
2021/6
2021
2022/6
2022
2023/6
2023
2024/6
Trade debtors turnover (days)  0.0 0.0 0.0 0.0 0.0  
Trade creditors turnover (days)  0.0 0.0 0.0 0.0 0.0  
Current assets / Net sales %  0.0% 0.0% 0.0% 0.0% 0.0%  
Net working capital  13,005.1 16,805.7 25,691.1 27,216.1 30,887.5  
Net working capital %  0.0% 0.0% 0.0% 0.0% 0.0%  

Employee efficiency 
2019
2020/6
2020
2021/6
2021
2022/6
2022
2023/6
2023
2024/6
Net sales / employee  0 0 0 0 0  
Added value / employee  999 1,045 1,091 674 706  
Employee expenses / employee  0 0 0 0 0  
EBITDA / employee  999 1,045 1,091 675 706  
EBIT / employee  949 1,009 1,049 635 673  
Net earnings / employee  818 827 531 536 633